In our lead program, we are developing small molecule kinase inhibitors targeting specific classes of BRAF kinase mutations (Class II and Class III BRAF mutations) that characterize subsets of melanoma, lung cancer and other solid tumors. While three BRAF targeted kinase inhibitor drugs targeting the Class I BRAF mutations have been approved by the FDA, no targeted therapies have been approved for Class II or Class III BRAF mutation-driven cancers, unlike the Class I BRAF mutations where three BRAF targeted kinase inhibitor drugs have been approved by the FDA. Patients with Class II or Class III BRAF mutations do not respond to existing targeted therapies, have few treatment options available to them and consequently have a poor prognosis. Initially, we plan to develop our lead RAF inhibitor candidates for the treatment of patients with melanoma and non-small cell lung cancer (NSCLC) subpopulations with Class II or Class III BRAF mutations that include specific BRAF point mutations (other than BRAF V600E), BRAF insertions/deletions (indels) and BRAF gene fusion events. We expect that our candidates may provide substantial clinical benefit to these cancer patients who are inadequately served by current therapies.